CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aileron Therapeutics, Inc., a biopharmaceutical company developing and advancing a revolutionary class of drugs called Stapled Peptides, today announced the company’s participation in several upcoming scientific conferences and biotechnology industry events.
- The 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, November 6-9, in Dublin, Ireland. Yong Chang, Ph.D., senior director, head of biology at Aileron, will present a poster entitled, “ATSP-7041, a Dual MDM2 and MDMX Targeting Stapled α-Helical Peptide Exhibits Potent in vitro and in vivo Efficacy in Xenograft Models of Human Cancer,” (abstract number 226) on Wednesday, November 7.
- FierceBiotech Webinar: Mastering Translational Medicine in Clinical Trials, hosted by John Carroll, editor of FierceBiotech, on Thursday, November 8 at 11 a.m. E.T. Hubert Chen, M.D., vice president, clinical development, endocrine and metabolic disease at Aileron, will be a featured speaker.
- Southeastern Regional Meeting of the American Chemical Society (SERMACS 2012), November 15-16, at the Raleigh Convention Center in Raleigh, NC. Tomi Sawyer, Ph.D., chief scientific officer, SVP discovery & innovative technologies at Aileron, will present “Stapled Peptide Drugs: Platform to Pipeline,” during the session Frontiers of Chemistry and Medicine: Novel Approaches for Peptide Drug Discover on Friday, November 16.
“This has been a very productive year for Aileron as we highlighted last week in our talk at The Seventh Peptide Therapeutics Symposium,” said Joseph A. Yanchik, III, president and chief executive officer of Aileron. “These upcoming forums provide an excellent opportunity to share additional updates across therapeutic areas on our Stapled Peptide drug programs as we prepare to enter the clinic early next year with our first-in-human Stapled Peptide.”
About Aileron Therapeutics
Aileron Therapeutics is creating the first new class of drugs in 20 years and is uniquely positioned to capitalize on key biological insights to attack complex diseases such as cancer, endocrine metabolic conditions and inflammation. By harnessing one of the most common, but elusive, structures in nature - the alpha helical peptide, we believe we can dramatically improve the treatment of these diseases and positively impact the lives of millions of patients around the globe. Aileron plans to initiate clinical development of its first Stapled Peptide drug in early 2013 with its wholly owned endocrine and metabolic disease program, ALRN-5281.
For more information, please visit www.aileronrx.com.